drugset / Trial / NCT03796182

Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants

NCT03796182

Phase 1 Completed 12 enrolled Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

This is a Phase 1, randomized, 2 way crossover, open label study of the effect of PF-04965842 on metformin (a probe for MATE1/2K activity) PK in healthy adult participants. The effect of PF-04965842 on N1-methylnicotinamide (NMN; an endogenous biomarker for MATE1/2K) PK and its correlation to the effect on metformin PK will also be assessed. Participants will be randomized to 1 of 2 treatment sequences as described below. A total of 12 healthy male and/or female participants will be enrolled in the study so that 6 participants will be enrolled in each treatment sequence. Each treatment sequence will consist of 2 periods.

Timeline

Start
2019-01-10
Primary completion
2019-02-13
Completion
2019-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Abrocitinib Small molecule 100 mg Oral
Subject Metformin Small molecule 500 mg

Indications

No indication recorded.